Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis

Tinatin Muradashvili,Mansen Yu,Sabrina L. Browning,Noffar Bar,Elan Gorshein,Terri L. Parker,Natalia Neparidze
DOI: https://doi.org/10.1038/s41375-024-02380-x
2024-08-22
Leukemia
Abstract:Monoclonal gammopathy (MG) represents a spectrum of related diseases, with monoclonal gammopathy of undetermined significance (MGUS) being the most prevalent. MGUS invariably precedes every case of smoldering multiple myeloma (SMM) and clinical multiple myeloma (MM). A risk of progression from MGUS to MM is about 1% per year [1], whereas for patients with SMM, it can reach up to 63% in 2 years [2]. While the association between MG and metabolic conditions has been recognized, the precise etiopathogenic mechanisms remain elusive. High body mass index is reported as a risk factor for MGUS and MM. Obesity may be recognized as a significant factor in the progression from MGUS to MM and higher mortality in MM [3]. Conversely, obese individuals may have improved progression free survival and overall survival in relapsed/refractory MM [4]. Yet, body mass index did not affect mortality in patients who underwent hematopoietic stem cell transplantation for MM [5].
oncology,hematology
What problem does this paper attempt to address?